A Closer Look-Discussion and Analysis o
2024 has been relatively quiet in terms of new accounting standards, with only two Accounting Standards Updates (ASUs) issued to date. However, changes are on the horizon. The Financial Accounting Standards Board (FASB) is expected to release additional ASUs covering the accounting for induced conversions of convertible debt instruments and the disaggregation of income statement […]
Definitive Healthcare H&D ABM Webinar – MedTech Dive
In the evolving world of healthcare, recognizing and understanding trends early can be crucial for strategic planning. This session will cover practical methods to spot and evaluate changes that could shape the market in 2025. We’ll discuss the complexities of medical coding for new technologies, how disruptive treatments like GLP-1 drugs are impacting established procedures […]
w_autc410 – Autodesk
In today’s rapidly evolving industrial landscape, manufacturers are increasingly turning to digital transformation to enhance their operations and ensure sustainable growth. By leveraging cutting-edge technologies, businesses can streamline their processes, improve efficiency, and drive innovation throughout the entire factory lifecycle. Why Digital Transformation is Essential for the Factory Lifecycle: Smart Manufacturing Optimized Production Processes End-to-End […]
A True Business License Compliance
Even the most efficient companies in North America struggle with the burden of business licenses and fear government repercussions from noncompliance. The tax and legal departments of these companies understand the consequences of noncompliance with regulations. When expanding operations, successful companies know it’s better to ask for permission than pay for forgiveness. However, achieving compliance […]
Salesforce Content Lead Extension – BioPharma Dive
Pharmaceutical companies must continue to drive innovation, even in the face of enormous challenges. In this guide, you’ll learn how Salesforce’s AI-powered life sciences platform can fuel innovation, uncover efficiencies, and help you deliver the experiences patients love. Learn how pharmaceutical companies can drive patient and customer engagement with an integrated platform that lets you: […]
The state of small
Small businesses are the backbone of the U.S. economy, accounting for more than half of the country’s workforce and creating two out of every three new jobs annually, according to the U.S. Small Business Administration. In recent years, small businesses have faced significant challenges, including increased competition from large chains and the impact of the […]
The Modern Workforce Planning
The Covid-19 pandemic brought about a significant shift in the talent landscape, with employees holding the upper hand due to talent shortages. However, as the pandemic subsides, the balance of power is shifting back toward employers. In this new era, it’s essential to have a game plan in place to navigate the inevitable changes in […]
Tailored antimicrobial therapy in critically ill patients:
The escalating threat of multidrug-resistant bacteria poses a significant challenge to hospitals worldwide. Critically ill patients are particularly vulnerable to these infections, making the selection and dosing of antimicrobials a complex and crucial task. At Bologna University Hospital in Italy, Professor Federico Pea and his team have developed a comprehensive and interdisciplinary program to tailor […]
Dizzying disclosures:
As sustainability regulations like Europe’s CSRD, California’s climate bills and the SEC’s proposed disclosure rule take effect, businesses must adopt an integrated approach to assess, manage and report climate risks. These regulations require transparent identification of physical and transition risks related to climate change, and actionable steps to mitigate them. Compliance demands more than reporting […]
w_peas08
Recent headlines reveal a troubling trend: missed endpoints, inconsistent results, and major failures in Alzheimer’s Disease (AD) clinical trials. Inadequate cognitive scales are cited as a key reason behind the 98% failure rate in Phase II and III trials. Take Lecanemab as an example—approved in the UK but deemed insufficient for NHS use due to […]